141 related articles for article (PubMed ID: 22221452)
1. Moving from continuous dopaminergic stimulation to continuous drug delivery in the treatment of Parkinson's disease.
Gershanik O; Jenner P
Eur J Neurol; 2012 Dec; 19(12):1502-8. PubMed ID: 22221452
[TBL] [Abstract][Full Text] [Related]
2. Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release.
Rascol O
Eur J Neurol; 2011 Mar; 18 Suppl 1():3-10. PubMed ID: 21255197
[TBL] [Abstract][Full Text] [Related]
3. Preventing and controlling dyskinesia in Parkinson's disease--a view of current knowledge and future opportunities.
Jenner P
Mov Disord; 2008; 23 Suppl 3():S585-98. PubMed ID: 18781676
[TBL] [Abstract][Full Text] [Related]
4. Wearing off, dyskinesia, and the use of continuous drug delivery in Parkinson's disease.
Jenner P
Neurol Clin; 2013 Aug; 31(3 Suppl):S17-35. PubMed ID: 23931952
[TBL] [Abstract][Full Text] [Related]
5. Continuous drug delivery in early- and late-stage Parkinson's disease as a strategy for avoiding dyskinesia induction and expression.
Jenner P; McCreary AC; Scheller DK
J Neural Transm (Vienna); 2011 Dec; 118(12):1691-702. PubMed ID: 21881838
[TBL] [Abstract][Full Text] [Related]
6. Role of dopamine receptor agonists in the treatment of early Parkinson's disease.
Bonuccelli U; Del Dotto P; Rascol O
Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S44-53. PubMed ID: 20123557
[TBL] [Abstract][Full Text] [Related]
7. Pulsatile or continuous dopaminomimetic strategies in Parkinson's disease.
Calandrella D; Antonini A
Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1():S120-2. PubMed ID: 22166407
[TBL] [Abstract][Full Text] [Related]
8. Continuous dopaminergic stimulation and novel formulations of dopamine agonists.
Stocchi F
J Neurol; 2011 May; 258(Suppl 2):S316-22. PubMed ID: 21560062
[TBL] [Abstract][Full Text] [Related]
9. Continuous dopaminergic delivery to minimize motor complications in Parkinson's disease.
Wright BA; Waters CH
Expert Rev Neurother; 2013 Jun; 13(6):719-29. PubMed ID: 23739008
[TBL] [Abstract][Full Text] [Related]
10. The concept of continuous dopaminergic stimulation: what we should consider when starting Parkinson's disease treatment.
Stocchi F
Neurodegener Dis; 2010; 7(1-3):213-5. PubMed ID: 20224289
[TBL] [Abstract][Full Text] [Related]
11. Treatment of Parkinson's disease: levodopa as the first choice.
Katzenschlager R; Lees AJ
J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
[TBL] [Abstract][Full Text] [Related]
12. Transdermal delivery of dopamine receptor agonists.
Reichmann H
Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S93-6. PubMed ID: 20123566
[TBL] [Abstract][Full Text] [Related]
13. Application of the concept of continuous dopaminergic stimulation for the management of Parkinson's disease.
Lv Q; Zhang B
Neurosci Bull; 2013 Oct; 29(5):661-9. PubMed ID: 23512740
[TBL] [Abstract][Full Text] [Related]
14. Deep brain stimulation and continuous dopaminergic stimulation in advanced Parkinson's disease.
Wolters ECh
Parkinsonism Relat Disord; 2007 Sep; 13 Suppl():S18-23. PubMed ID: 17702631
[TBL] [Abstract][Full Text] [Related]
15. From the MPTP-treated primate to the treatment of motor complications in Parkinson's disease.
Jenner P
Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S18-23. PubMed ID: 20123550
[TBL] [Abstract][Full Text] [Related]
16. The therapeutic concept of continuous dopaminergic stimulation (CDS) in the treatment of Parkinson's disease.
Stocchi F
Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S68-71. PubMed ID: 20083012
[TBL] [Abstract][Full Text] [Related]
17. Levodopa delivery systems: advancements in delivery of the gold standard.
Ngwuluka N; Pillay V; Du Toit LC; Ndesendo V; Choonara Y; Modi G; Naidoo D
Expert Opin Drug Deliv; 2010 Feb; 7(2):203-24. PubMed ID: 20095943
[TBL] [Abstract][Full Text] [Related]
18. Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson's disease.
Olanow CW; Obeso JA; Stocchi F
Nat Clin Pract Neurol; 2006 Jul; 2(7):382-92. PubMed ID: 16932589
[TBL] [Abstract][Full Text] [Related]
19. Dopamine receptor agonists in the treatment of advanced Parkinson's disease.
Stocchi F
Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S54-7. PubMed ID: 20123558
[TBL] [Abstract][Full Text] [Related]
20. Dopamine receptor agonists for Parkinson's disease.
Blandini F; Armentero MT
Expert Opin Investig Drugs; 2014 Mar; 23(3):387-410. PubMed ID: 24313341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
